For the majority of patients investigated in this study, clinical information about the gene mutations status was available featuring data on a myeloid gene panel comprising the genes ASXL1, BCOR, CALR, CBL, CEBPA, DNMT3A, ETV6, EZH2, FLT3-ITD, FLT3-TKD, GATA2, IDH1, IDH2, JAK2, KIT, KRAS, MLL-PTD, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1 and ZRSR2. As recorded in detail in Table 1, gene mutations occurred in 86% (31/36) of MDS patients, in 63% (5/8) of sAML patients and in 100% (9/9) of patients with de novo AML. This evidence concerns the gene GATA2 and myelodysplastic syndrome.